×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ETON – eton pharmaceuticals, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ETON
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/24
04:30 pm
eton
Eton Pharmaceuticals to Present at Piper Sandler 37th Annual Healthcare Conference on December 4th
Low
Report
Eton Pharmaceuticals to Present at Piper Sandler 37th Annual Healthcare Conference on December 4th
11/15
10:33 am
eton
Eton Pharmaceuticals (NASDAQ:ETON) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
Low
Report
Eton Pharmaceuticals (NASDAQ:ETON) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
11/12
04:30 pm
eton
Eton Pharmaceuticals to Participate at 16th Annual Craig-Hallum Alpha Select Conference on November 18th
Medium
Report
Eton Pharmaceuticals to Participate at 16th Annual Craig-Hallum Alpha Select Conference on November 18th
11/6
07:20 pm
eton
Eton Pharmaceuticals, Inc. (ETON) Reports Q3 Loss, Beats Revenue Estimates [Yahoo! Finance]
Medium
Report
Eton Pharmaceuticals, Inc. (ETON) Reports Q3 Loss, Beats Revenue Estimates [Yahoo! Finance]
11/6
04:40 pm
eton
Eton Pharmaceuticals Reports Third Quarter 2025 Financial Results [Yahoo! Finance]
Medium
Report
Eton Pharmaceuticals Reports Third Quarter 2025 Financial Results [Yahoo! Finance]
11/6
04:05 pm
eton
Eton Pharmaceuticals Reports Third Quarter 2025 Financial Results
Medium
Report
Eton Pharmaceuticals Reports Third Quarter 2025 Financial Results
10/24
11:09 pm
eton
Eton Pharmaceuticals Has Focused Growth But Valuation Limits Upside: Why I Choose To Hold [Seeking Alpha]
Low
Report
Eton Pharmaceuticals Has Focused Growth But Valuation Limits Upside: Why I Choose To Hold [Seeking Alpha]
10/23
04:30 pm
eton
Eton Pharmaceuticals to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025
Low
Report
Eton Pharmaceuticals to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025
Date
Time
Symbol
Company Name
Action
%Chg
11/6/2025
04:05 pm
eton
eton pharmaceuticals, inc.
MISS
Report
-11.7%
eton pharmaceuticals, inc.
8/7/2025
04:05 pm
eton
eton pharmaceuticals, inc.
BEAT
Report
12.3%
eton pharmaceuticals, inc.
5/13/2025
04:01 pm
eton
eton pharmaceuticals, inc.
MISS
Report
0.3%
eton pharmaceuticals, inc.
3/18/2025
06:50 am
eton
eton pharmaceuticals, inc.
MISS
Report
-4.6%
eton pharmaceuticals, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/4
07:31 am
eton
Form 8-K Eton Pharmaceuticals, For: Dec 04
Low
Report
Form 8-K Eton Pharmaceuticals, For: Dec 04
11/19
05:19 pm
eton
Form S-8 Eton Pharmaceuticals,
Medium
Report
Form S-8 Eton Pharmaceuticals,
11/18
04:17 pm
eton
Form 8-K/A Eton Pharmaceuticals, For: Dec 19
Low
Report
Form 8-K/A Eton Pharmaceuticals, For: Dec 19
11/6
04:29 pm
eton
Form 10-Q Eton Pharmaceuticals, For: Sep 30
High
Report
Form 10-Q Eton Pharmaceuticals, For: Sep 30
11/6
04:27 pm
eton
Form 8-K Eton Pharmaceuticals, For: Nov 06
High
Report
Form 8-K Eton Pharmaceuticals, For: Nov 06
10/30
03:19 pm
eton
Form SCHEDULE 13G Eton Pharmaceuticals, Filed by: VANGUARD GROUP INC
Low
Report
Form SCHEDULE 13G Eton Pharmaceuticals, Filed by: VANGUARD GROUP INC
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/27
Eton Pharmaceuticals Announces Acquisition of U.S Marketing Rights to Pediatric Orphan Drug Alkindi® Sprinkle
34.2%
10/22 Eton Pharmaceuticals Announces U.S. FDA Approval of Biorphen® (phenylephrine HCI) Injection 18.4%
4/8 Form D Eton Pharmaceuticals, 11.0%
3/25 Eton Pharmaceuticals Inc (NASDAQ: ETON) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 9.2%
3/12 Eton Pharmaceuticals Inc (NASDAQ: ETON) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 8.9%
1/28 Eton Pharmaceuticals Inc (NASDAQ: ETON) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $23.00 price target on the stock, up previously from $21.00. 8.0%
9/20 Eton Pharmaceuticals Inc (NASDAQ: ETON) is now covered by analysts at B. Riley. They set a "buy" rating and a $13.50 price target on the stock. 7.0%
3/16 Form 4 Eton Pharmaceuticals, For: Mar 12 Filed by: BRYNJELSEN SEAN 6.9%
4/6 Form 3 Eton Pharmaceuticals, For: Mar 26 Filed by: Opaleye Management Inc. 5.5%
11/13 Eton Pharmaceuticals Announces $10 Million Debt Facility with SWK Holdings 4.5%
10/22 Eton Pharmaceuticals Announces U.S. FDA Approval of Biorphen® (phenylephrine HCI) Injection 18.4%
4/8 Form D Eton Pharmaceuticals, 11.0%
3/25 Eton Pharmaceuticals Inc (NASDAQ: ETON) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 9.2%
3/12 Eton Pharmaceuticals Inc (NASDAQ: ETON) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 8.9%
1/28 Eton Pharmaceuticals Inc (NASDAQ: ETON) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $23.00 price target on the stock, up previously from $21.00. 8.0%
9/20 Eton Pharmaceuticals Inc (NASDAQ: ETON) is now covered by analysts at B. Riley. They set a "buy" rating and a $13.50 price target on the stock. 7.0%
3/16 Form 4 Eton Pharmaceuticals, For: Mar 12 Filed by: BRYNJELSEN SEAN 6.9%
4/6 Form 3 Eton Pharmaceuticals, For: Mar 26 Filed by: Opaleye Management Inc. 5.5%
11/13 Eton Pharmaceuticals Announces $10 Million Debt Facility with SWK Holdings 4.5%
TOP News Decliners
3/31
Eton Pharmaceuticals Inc (NASDAQ: ETON) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $4.50 price target on the stock.
-16.0%
3/5 Eton Pharmaceuticals, Inc. (ETON) CEO Sean Brynjelsen on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] -14.9%
3/17 Eton Pharmaceuticals Reports Positive Study Results for ET-101 (Topiramate Oral Solution) -14.8%
7/12 Eton Pharmaceuticals Provides Update on EM-100 Program -11.1%
3/18 Form 8-K Eton Pharmaceuticals, For: Mar 17 -10.4%
10/22 Form 8-K Eton Pharmaceuticals, For: Oct 22 -8.3%
3/30 Form 8-K Eton Pharmaceuticals, For: Mar 26 -8.3%
2/19 Eton Pharmaceuticals Provides Update on ET-105 Program -7.0%
10/23 Eton Pharmaceuticals Inc (NASDAQ: ETON) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.6%
8/5 Eton Pharmaceuticals Inc (NASDAQ: ETON) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock. -5.6%
3/5 Eton Pharmaceuticals, Inc. (ETON) CEO Sean Brynjelsen on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] -14.9%
3/17 Eton Pharmaceuticals Reports Positive Study Results for ET-101 (Topiramate Oral Solution) -14.8%
7/12 Eton Pharmaceuticals Provides Update on EM-100 Program -11.1%
3/18 Form 8-K Eton Pharmaceuticals, For: Mar 17 -10.4%
10/22 Form 8-K Eton Pharmaceuticals, For: Oct 22 -8.3%
3/30 Form 8-K Eton Pharmaceuticals, For: Mar 26 -8.3%
2/19 Eton Pharmaceuticals Provides Update on ET-105 Program -7.0%
10/23 Eton Pharmaceuticals Inc (NASDAQ: ETON) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.6%
8/5 Eton Pharmaceuticals Inc (NASDAQ: ETON) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock. -5.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: